Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Quarter under review - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Aug 19, 2003

    Pharma: Quarter under review

    After a lackluster performance in March quarter pharma companies made a remarkable turnaround in the June quarter. While the domestic pharma companies recorded strong revenue growth on the back of a revival in the anti-infectives segment, the MNC pharma companies managed to successfully control costs resulting in higher margins. In this context, let us briefly understand the performance of the industry as a whole during the June quarter.

    Domestic pharma companies
    (Rs m) June Q'02 June Q'03 Change
    Net sales 19,027 21,879 15.0%
    Operating profits 4,227 4,877 15.4%
    Operating profits margin (%) 22.2 22.3  
    Profit before tax 4,276 5,516 29.0%
    Profit after tax 3,411 4,476 31.2%
    Net profit margin (%) 17.9 20.5  
    P/E (annualised) (x)   17.9  

    The above figures are the aggregate of the quarterly results of five major domestic pharma companies – Ranbaxy, Cipla, Dr Reddy’s Laboratories, Nicholas Piramal and Wockhardt. As can be seen, the domestic pharma companies recorded 15% increase in the topline. This was possible due to higher off-takes in the domestic markets in the current quarter on account of postponement of VAT. Moreover, improvement in the product mix (Dr Reddy’s), sharp rise in the export of formulations (Wockhardt and Cipla) and consolidation (Nicholas Piramal) also contributed to the increase in the topline. While the domestic pharma companies were able to sustain the operating profit margins, a drop in the interest expenditure helped the companies in registering a sharp rise at the net level. The restructuring of the debt portfolio in favour of low cost ECBs (Ranbaxy and Nicholas Piramal) has helped the companies record a sharp 56% drop in the interest costs during the June quarter as compared to the corresponding previous quarter.

    The domestic pharma companies are trading at a P/E of 17.9x their annualised June Q’03 earnings. Going forward, increased R&D thrust, export focus, US government policy of encouragement of generics and inorganic growth strategy adopted by the companies indicate good prospects for the domestic pharma companies going forward. However, the inherent risk associated with new drug research, high legal expenses incurred in challenging existing patents, uncertainty in respect of DPCO and the market dynamics post 2005 remain a cause of concern.

    MNC pharma companies
    (Rs m) June Q'02 June Q'03 Change
    Net sales 5,612 6,096 8.6%
    Operating profits 1,093 1,282 17.3%
    Operating profits margin (%) 19.5 21.0  
    Profit before tax 1,138 1,414 24%
    Profit after tax 743 1,057 42.3%
    Net profit margin (%) 13.2 17.3  
    P/E (annualised) (x)   11.4  

    The above figures are the aggregate of the quarterly results of three major MNC pharma companies – GSK Pharma, Aventis and Novartis. Various strategies adopted by the MNC pharma companies like revitalization of the mature product portfolio by introducing product extensions and variants (Novartis), focus on power brands (GSK Pharma) and aggressive new product launches (Aventis) has resulted in a improvement in the topline. Further various measures taken like higher exports and closure of unviable units has helped the MNC pharma companies record an improvement in the operating profit margins.

    The MNC pharma companies are trading at a P/E of 11.4x annualised June Q’03 earnings. The MNC pharma companies are expected to gain immensely post 2005 on the back of their parent’s strong product portfolio. However, their high exposure to DPCO and a focus on the domestic markets remain the key causes for concern.

    Consolidated (Domestic + MNCs)
    (Rs m) June Q'02 June Q'03 Change
    Net sales 24,639 27,975 13.5%
    Operating profits 5,320 6,159 15.8%
    Operating profits margin (%) 21.6 22.0  
    Profit before tax 5,414 6,930 28%
    Profit after tax 4,154 5,533 33%
    Net profit margin (%) 16.9 19.8  
    P/E (annualised) (x)   16.6  

    On a consolidated basis, the pharma group (domestic plus MNCs) is trading at a P/E of 16.6x annualised June Q’03 earnings. Though the pharma industry has recorded strong growth in the current quarter, an across the sector rise in valuations especially in the mid-cap stocks does not appear to be fundamentally driven. In our view, though the pharma industry has good prospects in the long run, management vision of a company is key to its success. Only a company with a good business model will be able to stand up to the challenges that lie post 2005 period and grab opportunities for growth.



    Equitymaster requests your view! Post a comment on "Pharma: Quarter under review". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 03:37 PM